GILD - Gilead Sciences Inc

GILD

$147.83 2.60 (-1.73%) Last updated: Oct 13, 2026 18:11

52-Week Range

$147.83

$114.02 $147.83 $157.29

Fundamentals Overview

Gilead Sciences Inc is near the high of its 52-week range with moderate valuation, trading relatively flat today.

Valuation moderate

P/E 21.9 P/B 13.26 P/S 6.11

Risk (Beta)

0.4 — lower vol

BullzEye Analysis

Our composite tilts Hold on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.

Composite Signal

Sell

Buy

Hold — 52% confidence Risk: Lower Volatility — Beta 0.4. Diversify and only invest what you can afford to lose.

Pressures (Sell):

Volume below average

Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.

Key Stats

Market Cap

$186.53B

P/E (TTM)

21.89

EPS (TTM)

N/A

Dividend Yield

3.98%

52-Week Range

$114.02 - $157.29

Volume vs Avg

0.33x

33% of avg (Low)

Beta

0.4

About

Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer the...

Sector: Healthcare

Headquarters: US

Website: www.gilead.com

Beta: 0.4 (Less volatile than market)

Financial story & AI narrative

Open this tab to load the financial story.

Valuation & Ratios

Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.

Metric	Value
Valuation
P/E (TTM)	21.89
PEG (TTM)	N/A
P/B (TTM)	13.26
P/S (TTM)	6.11
Profitability
ROE (TTM)	-16.3%
ROA (TTM)	-5.81%
Revenue growth (YoY)	N/A
Net margin (TTM)	-10.64%
Gross margin (TTM)	79.6%
Operating margin (TTM)	-8.2%
Debt to equity (TTM)	2.22

Latest News

News loads when you open this tab.

Price Target, Ratings & Grades

Analyst price targets, consensus, rating snapshot, and institutional grades for GILD.

Loading analyst coverage...

Price target data is not available for this symbol from the current data source.

Stock Grades (Institutions)

No stock grades available for this symbol.

No price targets, ratings snapshot, or grades available for this symbol.